An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (BEV) in metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Hecht, J. [1 ]
Chiciac, T. [1 ]
Mitchell, E. [1 ]
Stella, P. [1 ]
Cohn, A. [1 ]
McCollum, D. [1 ]
Saleh, M. [1 ]
Marshall, A. [1 ]
Shahin, S. [1 ]
Deeter, R. [1 ]
机构：
[1] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：VII21 / VII22
页数：2
相关论文
共 50 条
  • [41] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [42] EFFICACY AND SAFETY OF TREATMENT WITH BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV plus CT: AGE SUBGROUP ANALYSIS FROM A RANDOMISED PHASE III INTERGROUP STUDY (ML18147)
    Bouche, O.
    Steffens, C.
    Andre, T.
    Bennouna, J.
    Sastre, J.
    Osterlund, P.
    von Moos, R.
    Reyes-Rivera, I.
    Sersch, M. A.
    Arnold, D.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 190 - 191
  • [43] Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC)
    Hochster, Howard S.
    Bendell, Johanna C.
    Cleary, James M.
    Foster, Paul
    Zhang, Wei
    He, Xian
    Hernandez, Genevive
    Iizuka, Koho
    Eckhardt, S. Gail
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [44] FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC).
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Antoniotti, Carlotta
    Marmorino, Federica
    Zoratto, Federica
    Bergamo, Francesca
    Brunetti, Isa Maura
    Pfanner, Elisabetta
    Masi, Gianluca
    Genovesi, Dario
    Filidei, Elena
    Giorgetti, Assuero
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Safety and efficacy of panitumumab monotherapy in patients with metastatic colarectal cancer (mCRC).
    Malik, I
    Hecht, JR
    Patnaik, A
    Venook, A
    Berlin, J
    Croghan, G
    Navale, L
    MacDonald, M
    Jerian, S
    Meropol, NJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 251S - 251S
  • [46] Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis
    Wang Ming
    Zheng Xiaofeng
    Ruan Xiaojiao
    Ye Bailiang
    Cai Long
    Lin Feizhuan
    Tu Jinfu
    Jiang Feizhao
    Li Shaotang
    [J]. CHINESE MEDICAL JOURNAL, 2014, 127 (03) : 538 - 546
  • [47] Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).
    Arnold, Dirk
    Andre, Thierry
    Bennouna, Jaafar
    Sastre, Javier
    Osterlund, Pia J.
    Greil, Richard
    Van Cutsem, Eric
    Von Moos, Roger
    Reyes-Rivera, Irmarie
    Bendahmane, Belguendouz
    Kubicka, Stefan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Efficacy outcomes by age from 5 observational or phase-4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC)
    Hubbard, J.
    Grothey, A.
    Van Cutsem, E.
    Hurwitz, H.
    Kozloff, M. F.
    Bekaii-Saab, T.
    Bennouna, J.
    Zafar, Y.
    Revil, C.
    Sommer, N.
    Srock, S.
    Arnold, D.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 42 - 43
  • [49] Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)
    Bennouna, J.
    Hiret, S.
    Borg, C.
    Bertaut, A.
    Bouche, O.
    Deplanque, G.
    Francois, E.
    Conroy, T.
    Ghiringhelli, F.
    des Guetz, G.
    Seitz, J-F.
    Artru, P.
    Stanbury, T.
    Charpentier, S.
    Denis, M.
    Adenis, A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [50] Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer
    Freeman, Daniel J.
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 633 - 645
12345